Alba Juan Juan

ORCID: 0000-0002-6634-6675
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Immunodeficiency and Autoimmune Disorders
  • Hepatitis B Virus Studies
  • Autoimmune and Inflammatory Disorders
  • Hepatitis C virus research
  • Eosinophilic Esophagitis
  • CNS Lymphoma Diagnosis and Treatment
  • Health Systems, Economic Evaluations, Quality of Life
  • Cancer Genomics and Diagnostics
  • Esophageal and GI Pathology
  • Liver Disease Diagnosis and Treatment
  • Genetic and phenotypic traits in livestock
  • Colorectal Cancer Treatments and Studies
  • Eosinophilic Disorders and Syndromes
  • Acute Lymphoblastic Leukemia research
  • Perfectionism, Procrastination, Anxiety Studies
  • Pharmacological Effects of Natural Compounds
  • Dysphagia Assessment and Management
  • Lymphoma Diagnosis and Treatment
  • Abdominal Surgery and Complications
  • Celiac Disease Research and Management
  • Radiopharmaceutical Chemistry and Applications
  • Autoimmune Bullous Skin Diseases
  • Healthcare cost, quality, practices

Hospital de Sant Joan Despí Moisès Broggi
2024

MeaningCloud (Spain)
2024

Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2019

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2019

Hospital Universitari Germans Trias i Pujol
2016-2017

Background: Golimumab efficacy data in ulcerative colitis (UC) are limited to anti-tumor necrosis factor a (TNF)-naive patients.The aim of this study was assess the short-term and long-term golimumab used as first, second, or third anti-TNF UC real-life clinical setting.Methods: This retrospective multicenter cohort included patients with moderate-to-severe treated golimumab.The primary endpoints were partial Mayo score response, failure-free survival, colectomy-free survival. Results:In 142...

10.1097/mib.0000000000001144 article EN Inflammatory Bowel Diseases 2017-07-01

Objectives: The objective of this study was (a) To know the prevalence and distribution extracolonic cancer (EC) in patients with inflammatory bowel disease (IBD); (b) estimate incidence rate EC; (c) evaluate association between EC treatment immunosuppressants anti-tumor necrosis factor (TNF) agents. Methods: This an observational cohort study. Inclusion criteria: IBD inclusion ENEIDA Project (a prospectively maintained registry) from GETECCU. Exclusion Patients before diagnosis IBD, lack...

10.1038/ajg.2017.96 article EN The American Journal of Gastroenterology 2017-05-23

Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate spread recurrence cancer. This study assesses impact use IMTs on development incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) a history malignancy.Patients IBD included ENEIDA registry without being exposed to were identified retrospectively reviewed compared regarding further treatment not by means...

10.14309/ajg.0000000000000210 article EN The American Journal of Gastroenterology 2019-04-08

Reproduction, Fertility and Development is an international journal publishing original research , review comment in the fields of reproduction developmental biology humans, domestic animals wildlife

10.1071/rdv37n1ab124 article EN Reproduction Fertility and Development 2024-12-12

We present a review of 9 patients (44.4% women, 67.7 +/- 7.3 years) who had undergone diverticular peroral endoscopic myotomy (D-POEM) for symptomatic epiphrenic diverticula (ED) at our Unit from July 2020 to April 2024. One patient received prior treatment, specifically, laparoscopic resection the diverticulum, Heller and partial funduplication in 2014 with clinical improvement. The predominant symptoms were dysphagia regurgitation average Eckardt Score (ES) 6 1,1. A co-existing esophageal...

10.17235/reed.2024.10770/2024 article EN publisher-specific-oa Revista Española de Enfermedades Digestivas 2024-01-01
Coming Soon ...